drugset
drugset / Trial / NCT03935685

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

NCT03935685 ↗

Phase 2 Active not recruiting 120 enrolled University of California, Irvine
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to estimate the ability of mirtazapine to reduce depression, nausea, and vomiting, and maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Of equal importance, the investigators will monitor the tolerability of Mirtazapine in these patients over the course of the study.

Timeline

Start
2019-02-26
Primary completion
2030-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirtazapine Other / unclassified 15 mg —
Subject Mirtazapine Other / unclassified 30 mg —
Subject Mirtazapine Other / unclassified 45 mg —

Indications

brain glioma